ME Newswire / Business Wire
MEMPHIS, Tenn. - Tuesday, August 27th 2013
Christie Medical Holdings, Inc., today announced the expansion of its industry-leading Christie Assure Program to hospitals and physician offices in over 40 countries using the HD VeinViewer® vein illumination products which project vascular imaging on the skin surface.
The five-year program includes warranty, access to online clinical education and an upgrade program to the latest Christie product platforms. An industry-first, the Christie Assure Program represents a significant leadership investment in seeing the end customer achieve utilization and results through Christie technologies.
Chris Schnee, GM and VP at Christie Medical Holdings, said, "We launched VeinViewerGS internationally in 2008. Today 3rd, 4th and 5th generation VeinViewers are being sold around the world. Through our technology leadership and support, we aim to help VeinViewer users achieve an increase in patient satisfaction, a potential reduction in patient risk and infection, and maximize healthcare economic benefits.”
The Christie Assure Program was built upon the results of a thorough survey where customers asked for help to achieve the same results which have proven the benefits of VeinViewer technology in clinical studies. Results show up to a 100 percent increase in first-stick success and patient satisfaction ratings and a 50 percent decrease in medically unnecessary PICC lines. The goal is to maximize the positive return each facility receives from its investment and to improve patient care.
Christie Assure Program terms apply.
Recently, the company’s three clinical studies encompassing 3,000 data points compared VeinViewer’s measurements to that of ultrasound, the industry gold standard. The studies, vetted and approved by Institutional Review Board (IRB) Services, demonstrated that VeinViewer measured accurate within half a millimeter on average, and for veins most commonly accessed for a peripheral IV (3mm-7mm wide), it projected near perfect vein widths (+/- 0.06mm).
VeinViewer has undergone ten stringent peer reviews since 2006. Third-party medical peer reviews demonstrate the statistically significant clinical effectiveness of VeinViewer, and often evaluate potential savings to the bottom line.
VeinViewer technology was developed with the aid of the engineering capabilities and resources of parent company Christie Digital Systems, a leading global visual technology firm with more than 80 years of experience in the projection systems industry. VeinViewer is the first and only device on the market to use: harmless near-infrared light, DLP® technologies, exclusive technology such as Active Vascular Imaging Navigation (AVIN™) providing the demanded Pre, During and Post-access (PDP) benefits, TrueView imaging accuracy in projected vein-widths which is three to ten times more accurate than competition, and technologies such as Df2 (Digital full field) to illuminate the only real-time HD digital image of subcutaneous vasculature and blood patterns directly onto the skin surface. Although designed for assistance in IV starts and blood draws, VeinViewer has proven beneficial in spider and varicose vein treatment.
To learn more about Christie product offerings please visit www.veinviewer.com.
About Christie Medical Holdings, Inc.
Christie Medical Holdings Inc. is a global company based in Memphis, Tenn., that discovers, develops and commercializes medical technologies. The company’s market-leading product, VeinViewer®, is a mobile vascular imaging system that allows health care providers to clearly see accessible vasculature as a real time HD image, directly on the surface of the skin. Christie Medical Holdings Inc. is owned by Christie Digital Systems Inc., a global visual technologies company and a subsidiary of Ushio Inc., Japan (JP:6925). For more information on Christie Digital Systems or Christie Medical Holdings, visit www.christiedigital.com.
Follow us on Twitter @veinviewer
DLP® is a registered trademark of Texas Instruments.
Christie Medical Holdings, Inc.
Carmen Robert, 519-572-5824